Drug Profile


Latest Information Update: 07 Oct 2002

Price : $50

At a glance

  • Originator Entropin (CEASED)
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Back injuries; Pain; Shoulder injuries; Sprains

Most Recent Events

  • 09 Sep 2002 Discontinued - Phase-II for Sprains in USA (Topical)
  • 09 Sep 2002 Discontinued - Phase-II for Back injuries in USA (Topical)
  • 09 Sep 2002 Discontinued - Preclinical for Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top